Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetoclax on digoxin pharmacokinetics, two semimechanistic dr...
Saved in:
Main Authors: | Ali A. Alhadab (Author), Ahmed Hamed Salem (Author), Kevin J. Freise (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
by: Nimita Dave, et al.
Published: (2019) -
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor
by: Ahmed Hamed Salem, et al.
Published: (2024) -
Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330
by: Larissa L. Silva, et al.
Published: (2024) -
Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
by: Soyoung Lee, et al.
Published: (2023) -
Characterizing Utilization and Outcomes of Digoxin Immune Fab for Digoxin Toxicity
by: Sophia Sheikh, et al.
Published: (2024)